基于模型的利福平与利福布汀药物相互作用特征的比较分析。
Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.
机构信息
Hospices Civils de Lyongrid.413852.9, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France.
Université Lyon, Université Lyon 1, UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France.
出版信息
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0104321. doi: 10.1128/AAC.01043-21.
Abstract
Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.
摘要
利福霉素广泛用于治疗分枝杆菌和葡萄球菌感染。利福平（RIF）引起的药物-药物相互作用（DDI）是一个主要问题。我们使用基于模型的方法来预测利福平（RIF）和利福布丁（RBT）对 217 种细胞色素 P450（CYP）底物的相互作用的程度。平均而言，低剂量 RIF 引起的 DDI 比 RBT 引起的 DDI 强两倍。与 RIF 相反，即使对于敏感的 CYP 底物，RBT 似乎也不太可能引起严重的 DDI。
相似文献
1
Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.基于模型的利福平与利福布汀药物相互作用特征的比较分析。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0104321. doi: 10.1128/AAC.01043-21.
2
Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.利福布汀和利福平对新鲜和冷冻保存的人肝细胞中细胞色素P450和UDP-葡萄糖醛酸基转移酶表达的比较作用。
Chem Biol Interact. 1999 Jun 1;121(1):37-48. doi: 10.1016/s0009-2797(99)00089-7.
3
Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs.涉及利福平、利福布汀与抗疟药物的药物相互作用的药代动力学和药效学
J Antimicrob Chemother. 2008 Nov;62(5):872-8. doi: 10.1093/jac/dkn330. Epub 2008 Aug 18.
4
Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.小鼠中安替比林肝脏和首过代谢的诱导：利福平与利福布汀的比较
Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):209-13. doi: 10.1007/BF03226373.
5
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.利福霉素类抗菌药物的比较药代动力学和药效学
Clin Pharmacokinet. 2001;40(5):327-41. doi: 10.2165/00003088-200140050-00002.
6
Critical Review: What Dose of Rifabutin Is Recommended With Antiretroviral Therapy?综述：抗逆转录病毒治疗时推荐使用何种剂量的利福布汀？
J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):138-52. doi: 10.1097/QAI.0000000000000944.
7
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.阻断细菌萘氢醌氧化和 ADP-核糖基化可提高利福霉素类药物对脓肿分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
8
In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.新型利福霉素对耐利福平结核分枝杆菌和MAIS复合群分枝杆菌的体外活性。
Tubercle. 1987 Sep;68(3):177-82. doi: 10.1016/0041-3879(87)90053-5.
9
Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.艾滋病患者同时服用去羟肌苷时，利福布汀在肠道的吸收未受影响。
Antimicrob Agents Chemother. 1997 Jul;41(7):1566-70. doi: 10.1128/AAC.41.7.1566.
10
Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.利福平、利福布汀和利福喷汀诱导原代人肝细胞中的流入和流出转运体以及细胞色素 P450 3A4。
Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9. doi: 10.1128/AAC.01124-13. Epub 2013 Sep 23.
引用本文的文献
1
Development and hepatotoxicity of rifamycin derivatives.利福霉素衍生物的研发与肝毒性
Expert Opin Drug Metab Toxicol. 2025 Jun 29:1-8. doi: 10.1080/17425255.2025.2525451.
2
Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT.造血干细胞移植后的结核病：欧洲血液与骨髓移植学会传染病工作组的回顾性研究
Bone Marrow Transplant. 2025 May;60(5):603-616. doi: 10.1038/s41409-025-02530-4. Epub 2025 Feb 25.
3
Characteristics of and treatment outcomes in rifampicin-intolerant patients.利福平不耐受患者的特征及治疗结果
IJTLD Open. 2024 Apr 1;1(4):160-165. doi: 10.5588/ijtldopen.23.0466. eCollection 2024 Apr.
4
In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022.2018 年至 2022 年美国缓慢生长非结核分枝杆菌的体外药敏模式。
J Antimicrob Chemother. 2023 Dec 1;78(12):2849-2858. doi: 10.1093/jac/dkad317.
5
Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations.基于静脉内纳米材料的利福布汀制剂生物制药相似性检测中区室分析与非房室分析的比较
Pharmaceutics. 2023 Apr 17;15(4):1258. doi: 10.3390/pharmaceutics15041258.
6
Novel approaches in the treatment of Hansen's disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States.麻风病治疗的新方法：美国每月使用利福平、莫西沙星和米诺环素（RMM）联合化疗的病例系列
Ther Adv Infect Dis. 2022 Nov 8;9:20499361221135885. doi: 10.1177/20499361221135885. eCollection 2022 Jan-Dec.
7
Infective Endocarditis in the Elderly: Challenges and Strategies.老年人感染性心内膜炎：挑战与策略
J Cardiovasc Dev Dis. 2022 Jun 17;9(6):192. doi: 10.3390/jcdd9060192.
8
A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections.利福布汀治疗葡萄球菌人工假体感染的病例系列
Microbiol Spectr. 2022 Jun 29;10(3):e0038422. doi: 10.1128/spectrum.00384-22. Epub 2022 May 11.
9
Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Complex: A meta-Analysis Study.基于利福布汀与基于利福平的方案治疗复杂性疾病的比较：一项荟萃分析研究。
Front Pharmacol. 2021 Sep 7;12:693369. doi: 10.3389/fphar.2021.693369. eCollection 2021.
本文引用的文献
1
Rifabutin to the Rescue?利福布汀来救援？
J Infect Dis. 2020 Oct 1;222(9):1422-1424. doi: 10.1093/infdis/jiaa403.
2
Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis.利福布汀和利福喷汀治疗异物性骨髓炎大鼠模型耐甲氧西林金黄色葡萄球菌感染的新用途。
J Infect Dis. 2020 Oct 1;222(9):1498-1504. doi: 10.1093/infdis/jiaa401.
3
Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics.肝细胞转录特征可预测利福霉素类抗生素的药物相互作用潜力。
Sci Rep. 2020 Jul 28;10(1):12565. doi: 10.1038/s41598-020-69228-z.
4
Interpretation of Cytochrome P-450 Inhibition and Induction Effects From Clinical Data: Current Standards and Recommendations for Implementation.从临床数据解读细胞色素 P-450 的抑制和诱导作用：现行标准和实施建议。
Clin Pharmacol Ther. 2021 Jan;109(1):82-86. doi: 10.1002/cpt.1918. Epub 2020 Jun 20.
5
Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.基于药代动力学的间变性淋巴瘤激酶抑制剂的药物相互作用：综述。
Drug Des Devel Ther. 2020 Apr 30;14:1663-1681. doi: 10.2147/DDDT.S249098. eCollection 2020.
6
Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.临床药物-药物相互作用研究评估 P 糖蛋白抑制剂、CYP3A 抑制剂和 CYP3A 诱导剂对健康受试者纳洛肽药代动力学的影响。
Clin Drug Investig. 2020 Jun;40(6):529-540. doi: 10.1007/s40261-020-00902-w.
7
Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.伊曲康唑和利福平对健康日本受试者中非甾体类盐皮质激素受体阻滞剂依普利酮单剂量药代动力学的影响。
Br J Clin Pharmacol. 2020 Oct;86(10):2070-2079. doi: 10.1111/bcp.14302. Epub 2020 May 13.
8
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.CYP3A 诱导和抑制对新型神经免疫调节剂拉喹莫德的药代动力学的影响。
Clin Pharmacol Drug Dev. 2020 Nov;9(8):1015-1024. doi: 10.1002/cpdd.785. Epub 2020 Apr 1.
9
Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin.利福霉素类药物对金黄色葡萄球菌的抗生物膜和骨内活性：利福布汀具有有前景的体外特性。
J Antimicrob Chemother. 2020 Jun 1;75(6):1466-1473. doi: 10.1093/jac/dkaa061.
10
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.利福平与伊曲康唑对亚洲和非亚洲健康受试者中赞布替尼（一种布鲁顿酪氨酸激酶抑制剂）药代动力学的影响。
Cancer Chemother Pharmacol. 2020 Feb;85(2):391-399. doi: 10.1007/s00280-019-04015-w. Epub 2019 Dec 26.
Zotero 插件